OTCMKTS:OSIROsiris Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Osiris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $18.99 0.00 (0.00 %) (As of 05/26/2020 04:00 PM ET) Add Compare Share Today's Range$18.99Now: $18.99▼$18.9950-Day Range$18.99MA: $18.99▼$18.9952-Week Range$7.01Now: $18.99▼$19.30VolumeN/AAverage Volume202,293 shsMarket Capitalization$655.69 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Osiris Therapeutics. Previous Next 2.0 Community Rank Outperform VotesOsiris Therapeutics has received 116 “outperform” votes. (Add your “outperform” vote.)Underperform VotesOsiris Therapeutics has received 173 “underperform” votes. (Add your “underperform” vote.)Community SentimentOsiris Therapeutics has received 59.86% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Osiris Therapeutics and other stocks. Vote “Outperform” if you believe OSIR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe OSIR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldOsiris Therapeutics does not currently pay a dividend.Dividend GrowthOsiris Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Osiris Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders43.40% of the stock of Osiris Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.28% of the stock of Osiris Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.60 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolOTCMKTS:OSIR Previous SymbolNASDAQ:OSIR CUSIP68827R10 CIK1360886 Webwww.osiristx.com Phone443-545-1800Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares34,528,000Market Cap$655.69 million Next Earnings DateN/A OptionableOptionable OTC:OSIR Rates by TradingView Receive OSIR News and Ratings via Email Sign-up to receive the latest news and ratings for OSIR and its competitors with MarketBeat's FREE daily newsletter. Osiris Therapeutics (OTCMKTS:OSIR) Frequently Asked Questions How has Osiris Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Osiris Therapeutics' stock was trading at $18.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OSIR stock has increased by 0.0% and is now trading at $18.99. View which stocks have been most impacted by Coronavirus. Has Osiris Therapeutics been receiving favorable news coverage? News articles about OSIR stock have trended extremely negative recently, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Osiris Therapeutics earned a news sentiment score of -4.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutOsiris Therapeutics. Who are some of Osiris Therapeutics' key competitors? Some companies that are related to Osiris Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Ionis Pharmaceuticals (IONS). View all competitors. What other stocks do shareholders of Osiris Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Osiris Therapeutics investors own include Sierra Wireless (SWIR), MiMedx Group (MDXG), Achillion Pharmaceuticals (ACHN), Fate Therapeutics (FATE), Ionis Pharmaceuticals (IONS), Mallinckrodt (MNK), Catabasis Pharmaceuticals (CATB), Cytokinetics (CYTK), Depomed (DEPO) and EXACT Sciences (EXAS). Who are Osiris Therapeutics' key executives? Osiris Therapeutics' management team includes the following people: Mr. Jason Keefer, Interim Pres & CEO (Age 46)Dr. Alla N. Danilkovitch, Chief Scientific Officer (Age 54)Mr. Joel David Rogers, Interim Chief Financial Officer (Age 56)Mr. Edward Yip, Chief Legal Officer & Corp. Sec.Mr. Laine Dyess, VP of Sales What is Osiris Therapeutics' stock symbol? Osiris Therapeutics trades on the OTCMKTS under the ticker symbol "OSIR." How do I buy shares of Osiris Therapeutics? Shares of OSIR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Osiris Therapeutics' stock price today? One share of OSIR stock can currently be purchased for approximately $18.99. How big of a company is Osiris Therapeutics? Osiris Therapeutics has a market capitalization of $655.69 million. What is Osiris Therapeutics' official website? The official website for Osiris Therapeutics is www.osiristx.com. How can I contact Osiris Therapeutics? Osiris Therapeutics' mailing address is 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD, 21046. The biotechnology company can be reached via phone at 443-545-1800 or via email at [email protected] This page was last updated on 5/27/2020 by MarketBeat.com Staff
